GoldsteinAL. New-onset Graves' disease in the postpartum period. J Midwifery Womens Health, 2013; 58:211–214.
2.
AlexanderEK. Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum. Thyroid, 2017; 27:315–389.
3.
IdeA, AminoN, KangS, et al.Differentiation of postpartum graves' thyrotoxicosis from postpartum destructive thyrotoxicosis using antithyrotropin receptor antibodies and thyroid blood flow. Thyroid, 2014; 24:1027–1031.
4.
NicholsonWK, RobinsonKA, SmallridgeRC, LadensonPW, PoweNR. Prevalence of postpartum thyroid dysfunction: A quantitative review. Thyroid, 2006; 16:573–582.
5.
Stagnaro-GreenA. Approach to the patient with postpartum thyroiditis. J Clin Endocrinol Metab, 2012; 97:334–342.
6.
PearceEN. Management of thyrotoxicosis: Preconception, pregnancy, and the postpartum period. Endocr Pract, 2018; 25:62–68.
7.
GaberščekS, ZaletelK. Thyroid physiology and autoimmunity in pregnancy and after delivery. Expert Rev Clin Immunol, 2011; 7:697–707.
8.
LazarusJH. Clinical manifestations of postpartum thyroid disease. Thyroid, 1999; 9:685–689.
9.
Dato CDi, MantovaniG, MorettiC, et al.Selenium supplementation in the management of thyroid autoimmunity during pregnancy: Results of the “Serena Study” a randomized, double-blind, placebo-controlled trial. Endocr Abstr, 2017; DOI:10.1530/endoabs.49.oc9.5
10.
NegroR, GrecoG, MangieriT, PezzarossaA, DazziD, HassanH. The influence of selenium supplementation on postpartum thyroid status in pregnant women with thyroid peroxidase autoantibodies. J Clin Endocrinol Metab, 2007; 92:1263–1268.
